Adoptive transfer of ex  vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer

In this study, ex  vivo expanded cytotoxic Vγ9Vδ2 T cells isolated from human peripheral blood were tested for their anti-cancer efficacy in combination with zoledronic acid (ZOL), using a mouse model of osteolytic breast cancer. In vitro, expanded Vγ9Vδ2 T cells were cytotoxic against a panel of human breast c ancer cell lines, and ZOL pre-treatment further sensitised breast cancer cells to killing by Vγ9Vδ2 T cells.

Source: Cancer Letters - November 15, 2016 Category: Cancer & Oncology Authors: Aneta Zysk, Mark O. DeNichilo, Vasilios Panagopoulos, Irene Zinonos, Vasilios Liapis, Shelley Hay, Wendy Ingman, Vladimir Ponomarev, Gerald Atkins, David Findlay, Andrew Zannettino, Andreas Evdokiou Tags: Original Article Source Type: research